[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-disease":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,48,74,110,136,162,182,203,226,250,273,296,327,346,370,394,418,441,474,504,530,551,578,605,629],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100053993","well-being-program-for-caregivers-of-patients-with-advanced-cardiac-and-pulmonary-disease-100053993",false,"NCT07685912","Well-being Program for Caregivers of Patients With Advanced Cardiac and Pulmonary Disease","Enhancing Caregiver Wellbeing: The Role of Exercise, Nutrition, and Stress Management for Caregivers of Patients With Advanced Cardiac and Pulmonary Disease","INCLUSION CRITERIA (CAREGIVERS):\n\n* Informal (unpaid) caregivers aged 18 years or older\n* Identified as the primary caregiver of a patient with advanced cardiac or pulmonary disease receiving outpatient palliative care at Toronto General Hospital\n* Ability to provide informed consent\n\nEXCLUSION CRITERIA (CAREGIVERS):\n\n* Presence of any medical condition where moderate physical activity or exercise training would be contraindicated (e.g., unstable cardiovascular disease, recent injury)\n* Significant cognitive impairment or language barrier that would interfere with completing study procedures\n* Lack of access to a phone or internet connection to enable virtual participation\n\nINCLUSION CRITERIA (Patients):\n\n* Aged 18 years or older\n* Diagnosis of advanced cardiac or pulmonary disease and currently receiving outpatient palliative care at Toronto General Hospital\n* Ability to provide informed consent\n\nEXCLUSION CRITERIA (Patients):\n\n* Significant cognitive impairment or language barrier that would interfere with completing study procedures\n* Medical instability that would preclude participation in an interview or completion of questionnaires, as determined by the clinical team\n* Lack of access to a phone or internet connection to enable virtual participation","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Caregivers provide essential support for people living with advanced heart or lung disease, including daily tasks, emotional support, and help with medical care. Although their role is vital, caregivers often experience high levels of stress, fatigue, and challenges with their own health and well-being. This study will test whether it is possible and practical to offer an 8-week wellness program for caregivers that is delivered virtually in their homes. The program includes personalized strategies for physical activity or exercise, healthy eating, and stress management. It will be tailored to the individual needs and schedules of caregivers and supported by regular virtual check-ins with health professionals. We will evaluate whether caregivers find the program acceptable, safe, and feasible to follow. This includes looking at how many caregivers agree to participate, how many complete the program, whether they can follow the activities, and whether they are satisfied with the experience. The study will also explore whether participating in the program may lead to improvements in caregiver quality of life, stress, and confidence in the caregiving role.",[27,28,29],"Caregiver","Cardiac Disease","Pulmonary Diseases",[31,32,33,34],"Exercise","Nutrition","Stress management","Well-being","NOT_YET_RECRUITING","2026-07-09",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":21},"2026-07-15",{"date":43,"type":21},"2028-03-30",{"name":45,"class":46},"University Health Network, Toronto","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100425721","boston-scientific-rhythm-management-registry-socrates-100425721","NCT04823663","BoStOn SCientific Rhythm MAnagemenT REgiStry (SOCRATES)","BoStOn SCientific Rhythm MAnagemenT REgiStry","SOCRATES","Inclusion Criteria:\n\n1. Subject is willing and capable of providing informed consent and\u002For to give approval to collect\u002Fstore\u002Fprocess personal health information by the sponsor or such consent\u002Fapproval is provided by a legally designated representative, if required by local law or regulation.\n2. Subject is (one criterion must be fulfilled) a. prospectively scheduled for a procedure involving i. use of a BSC EP Ablation product or BSC Capital Equipment product or ii. a BSC CRM product implant or b. retrospectively enrolled no more than 10 days after the index procedure and all data necessary for appropriate reporting of all past visits is available and complete including i. the procedure where being diagnosed or treated with at least 3 separate BSC EP Ablation products\u002Fcomponents or BSC Capital Equipment products\u002Fcomponents or ii. the BSC CRM product implant.\n\nExclusion Criteria:\n\n1. Subject is foreseen not to be followed at the enrolling center for at least 1 year after an implant procedure (CRM) or at least 1 month (EP).\n2. Subject is receiving diagnosis or therapy by means of any product, that is not approved for commercial use at the time of implant\u002Fprocedure.",{"count":57,"type":21},12500,"10 Years","OBSERVATIONAL","SOCRATES is part of Boston Scientific's (BSC) Post-market surveillance system. The implementation of such systems is mandatory per local regulations such as the Regulation '(EU) 2017\u002F745 of the European Parliament and of the Council of 5 April 2017 on medical devices' or short Medical Device Regulation (MDR). The SOCRATES design is therefore based on the BSC's commitment as well as external regulatory requirements to proactively and systematically gather, record and analyze relevant data on the quality, performance and safety of devices throughout their entire lifetime.",[28],"RECRUITING","2026-06-25",{"date":65,"type":39},"2026-06-29",{"date":67,"type":39},"2021-03-31",{"date":69,"type":21},"2030-12-31",{"name":71,"class":72},"Boston Scientific Corporation","INDUSTRY",26,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":92,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100609654","left-bundle-branch-area-pacing-lbbap-pmcf-study-100609654","NCT07217392","Left Bundle Branch Area Pacing (LBBAP) PMCF Study","LBBAP PMCF","Inclusion Criteria:\n\n1. Meets current clinical practice guidelines for implantation of Tendril STS 2088TC or UltiPace LPA1231 lead in the Left Bundle Branch Area\n2. Are ≥ 18 years of age or age of legal consent, whichever age is greater.\n3. Subject is willing to comply with clinical investigation procedures and agrees to return to clinic for all required follow-up visits, tests, and exams.\n4. Subject has been informed of the nature of the clinical investigation, agrees to its provisions and has provided a signed written informed consent, approved by the IRB\u002FEC.\n\nExclusion Criteria:\n\n1. Patient meets a standard contraindication for lead implant including:\n\n   1. the presence of tricuspid atresia\n   2. patients with mechanical tricuspid valves\n   3. patients who are expected to be hypersensitive to a single dose of one milligram of dexamethasone sodium phosphate\n2. Patient is currently implanted with a pacemaker, ICD, or CRT-D\u002FP device\n3. Patient has had a previous unsuccessful attempt to place a lead in the LBB area\n4. Patient has planned cardiac surgical procedures or interventional measures within 3 months after implant\n5. Patient is expected to receive a heart transplant within 6 months\n6. Patient life expectancy less than 6 months\n7. Patient has the presence of another life-threatening, underlying illness separate from their cardiac disorder\n8. Patient is enrolled or planning to enroll in another clinical trial that might confound the results of the present study\n9. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period.\n10. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation.",{"count":82,"type":21},200,[24],"The objective of this study is to evaluate the safety and effectiveness of LBBA pacing\u002Fsensing in patients implanted with the Tendril STS 2088TC or UltiPace LPA1231 lead through 6 months post-implant.",[86,87,88,89,28,90,91],"Bradycardia","Right Ventricular Pacing","Heart Failure","Atrial Fibrillation (AF)","Left Bundle Branch Area Pacing","Conduction System Pacing",[93,94,95,96,97,98,99],"Right ventricular pacing","cardiac disease","heart failure","atrial fibrillation","bradycardia","left bundle branch area pacing","conduction system pacing","2026-04-22",{"date":102,"type":39},"2026-04-24",{"date":104,"type":39},"2025-07-24",{"date":106,"type":21},"2027-04-30",{"name":108,"class":72},"Abbott Medical Devices",13,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":17,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100634655","digital-diagnosis-of-cardiac-sound-in-pediatric-patients-di-sound-study-100634655","NCT07542509","Digital diagnoSis of Cardiac sOUNd in peDiatric Patients [DI-SOUND Study]","DI-SOUND","Inclusion criteria:\n\n* Age \\\u003C 30 days\n* Signed informed consent obtained from parent(s) or representative(s)\n\nExclusion criteria:\n\n* Inability to acquire a diagnostic echocardiogram\n* Weight less than 1.5Kg",true,"7 Days","30 Days",{"count":121,"type":21},1000,"Neonatal screening procedures for potentially life-threatening congenital cardiovascular diseases (i.e., duct-dependent systemic or pulmonary circulation), currently implemented at the national level, rely primarily on cardiovascular physical examination performed by a neonatologist. More recently, this approach has been complemented by the assessment of hemoglobin oxygen saturation at both the upper and lower extremities (pre- and post-ductal saturation) in order to improve diagnostic sensitivity, although this practice has not yet been uniformly adopted nationwide. Converging evidence indicates that these screening strategies are affected by significant limitations in both sensitivity (failure to identify affected individuals) and specificity (false-positive findings in healthy subjects). These limitations are associated with substantial overall costs for the healthcare system. Failure to correctly identify affected neonates may result in increased morbidity and mortality, whereas overdiagnosis leads to unnecessary second-level diagnostic investigations and imposes a considerable psychological burden on families, who remain understandably anxious until diagnostic confirmation is achieved.\n\nThe aim of the present research project (proof-of-concept study) is to develop a digital classifier capable to categorize heart sounds with commercially available digital stethoscopes into a binary classification system distinguishing physiological from pathological sounds. The derivation phase will be followed by a prospective validation phase, in which the classifier will be applied to assess its diagnostic performance. This phase will also evaluate the economic impact of the digital screening approach compared with standard practice.\n\nDuring the derivation phase, neonates with known cardiovascular status, as determined by prior echocardiographic assessment (including both healthy subjects and those with congenital heart disease), will be enrolled. Heart sounds will be recorded in a quiet environment under standard clinical conditions, without sedation. Digital recordings will be stored in WAV format and analyzed to develop a binary classification algorithm capable of distinguishing healthy from pathological cases. Following development, the classifier will be prospectively applied to a validation cohort of neonates undergoing conventional cardiovascular screening (clinical examination and pre- and post-ductal pulse oximetry), followed by classification using the digital tool under investigation. All participants will subsequently undergo confirmatory echocardiography. Diagnostic performance metrics, including sensitivity, specificity, positive and negative predictive values, and likelihood ratios, will be calculated for both the digital and conventional screening modalities. Furthermore, the number of missed pathological cases and the number of unnecessary second-level investigations resulting from false-positive findings will be used to define the economic benefit profile of the proposed screening strategy. Monte Carlo simulation techniques will be employed to extrapolate these findings at the national level, using ISTAT data on birth rates and disease prevalence.\n\nIt is anticipated that the development of a digital classifier for the binary classification of neonatal heart sounds will be feasible. Moreover, it is expected that this tool will demonstrate superior diagnostic performance compared with current neonatal screening strategies, with beneficial implications not only for the accurate identification of affected and healthy neonates but also for reducing overall healthcare costs associated with missed diagnoses and inappropriate overdiagnosis.",[28,124,125],"Auscultation of Heart","Machine Learning","2026-04-15",{"date":128,"type":39},"2026-04-21",{"date":130,"type":39},"2024-07-18",{"date":132,"type":21},"2027-01-01",{"name":134,"class":46},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",5,{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100633860","efferon-lps-hemoadsorption-in-cardiac-surgery-patients-100633860","NCT07532174","Efferon LPS Hemoadsorption in Cardiac Surgery Patients","Intraoperative and Early Postoperative Use of Lipopolysaccharide Adsorption (Efferon LPS) in Cardiac Surgery Patients to Reduce the Incidence of Multiple Organ Dysfunction Syndrome in the Postoperative Period","Inclusion Criteria:\n\n* Adult patients undergoing elective or emergency cardiac surgery with the use of cardiopulmonary bypass (CPB).\n* EuroSCORE II ≥6%\n\nExclusion Criteria:\n\n* Procalcitonin ≥2 ng\u002FmL\n* Severe chronic liver disease, defined as Child-Pugh class C (\\>10 points) or clinically manifest hepatic failure\n* Dialysis-dependent chronic kidney disease (CKD)\n* Ongoing immunosuppressive therapy, including corticosteroids or cytotoxic agents, excluding standard perioperative medications\n* Any other clinical condition that, in the investigator's opinion, would preclude the patient's participation in the study",{"count":144,"type":21},60,[24],"This randomized controlled study aims to evaluate the efficacy and safety of intraoperative and early postoperative hemoadsorption using the Efferon® LPS device in patients undergoing cardiac surgery with cardiopulmonary bypass in reducing the incidence and severity of multiple organ dysfunction syndrome (MODS) in the postoperative period. Each patient in the treatment group will undergo two hemoadsorption sessions: first during cardiopulmonary bypass (CPB) at the time of cardiac surgery, with the duration determined by the CPB time, and second within 24 hours postoperatively, for a minimum duration of 6 hours.",[28,148],"Multiple Organ Dysfunction Syndrome",[150,151,152,153],"Hemoadsorption","Hemoperfusion","Extracorporeal therapy","LPS adsorption","2026-04-09",{"date":126,"type":39},{"date":126,"type":21},{"date":158,"type":21},"2028-01-31",{"name":160,"class":72},"Efferon JSC",3,{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":117,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":47},"100538690","multivariate-approach-to-the-numerical-assessment-of-cortical---autonomic---vascular-dynamic-interplay-100538690","NCT06294119","Multivariate Approach to the Numerical Assessment of Cortical - Autonomic - VAscular Dynamic Interplay","Inclusion Criteria:\n\n* age older than 18 years\n* spontaneous sinus rhythm\n* signed informed consent\n* indication to heart surgery\n\nExclusion Criteria:\n\n* age lower than 18 years\n* absence of sinus rhythm\n* pregnancy\n* impossibility of informed consent",{"count":20,"type":21},[24],"MANCAVA sets out fundamental methodologies for characterizing human fundamental physiological system interactions at a whole-body level, particularly focusing on the interplay among cortical brain activity, autonomic function, and cerebrovascular autoregulatory mechanisms. By investigating the complex, time-varying mechanisms underlying the multisystem dynamic interactions, novel methods linking various brain areas and reflex functions to target organs and districts such as heart and circulatory system are proposed with the clinical aim linked to the emerging topic of depression.\n\nIn this scenario, proper new mathematical tools will allow a significant leap from the current state of the art, paving the way towards a new understanding of leading comorbid contributors to global diseases such as cardiac and cerebrovascular morbidity in mood disorders. In turn, this will provide an integration among physiological and psychological dimensions for a more holistic view on depression.\n\nResearchers, professionals, and patients will all benefit from a comprehensive assessment of brain-mind-body interplay, leading to the new extended definition of default mode\u002Fmood network, neurovascular-evoked responses to autonomic stimuli, brain-autonomic consequences of emotional responses, and physiological substrates of depressive states.",[28,172],"Depression","2026-03-23",{"date":175,"type":39},"2026-03-27",{"date":177,"type":39},"2025-09-30",{"date":179,"type":21},"2029-02-28",{"name":181,"class":46},"IRCCS Policlinico S. Donato",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":17,"minAge":189,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":47},"100630631","cardiac-clearance-vs-g60-hip-frailty-index-100630631","NCT07490184","Cardiac Clearance vs G60 Hip Frailty Index","Cardiac Clearance vs G60 Hip Frailty Index in Trauma","Inclusion Criteria:\n\n≥60 years old Included in the Methodist Dallas Medical Center Trauma Registry Documented orthopedic injury with surgical management\n\nExclusion Criteria:\n\n\\\u003C60 years old Prisoners, pregnant persons, or other protected populations","60 Years",{"count":191,"type":21},100,"The primary objective of this study is to establish a data repository that will be permissive of quality improvement studies\u002Fobservations specific to postoperative mortality outcomes for geriatric patients with orthopedic injuries based on Orthopedic Hip Frailty Score and preoperative cardiac clearance predictors.",[28],"2026-03-18",{"date":196,"type":39},"2026-03-24",{"date":198,"type":21},"2026-02",{"date":200,"type":21},"2028-02",{"name":202,"class":46},"Methodist Health System",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":47},"100595464","phase-2-factor-viii-inhibitor-bypass-activity-feiba-versus-fresh-frozen-plasma-as-first-line-therapy-for-bleeding-after-cardiac-surgery-100595464","NCT07032792","Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 18 years or above\n* Undergoing nonemergent non-coronary cardiac surgery with the use of cardiopulmonary bypass\n* Patient with microvascular bleeding requiring factor transfusion as deemed by the patient care team\n\nExclusion Criteria:\n\n* Contraindication to the administration of FEIBA or known anaphylactic or severe hypersensitivity reaction to FEIBA or any of its components\n* Disseminated intravascular coagulation\n* Acute thrombosis or embolism, including myocardial infarction\n* Pregnancy\n* Patients that are not able or do not want to consent for themselves\n* Patients with known coagulation disorders\n* Patients who received coronary artery bypass surgery\n* Patients who received transplants or ventricular assist devices\n* Patients on extracorporeal membrane oxygenator support\n* Patients with heparin induced thrombocytopenia\n* Patients who do not wish to receive blood products even when it is deemed medically necessary",{"count":210,"type":21},140,[212],"PHASE2","Coagulopathic-induced bleeding after cardiopulmonary bypass in cardiac surgery patients is common and is associated with adverse outcomes in cardiac surgery. The hypothesis of the study is that FEIBA will be a more effective treatment than standard of care (FFP) in cardiac surgery patients who have coagulopathic-induced bleeding. This study is being conducted to determine the efficacy of FEIBA versus FFP as first line therapy in correcting coagulopathic induced microvascular bleeding in cardiac surgery patients.",[28,215,216],"Surgery","Bleeding","2026-03-09",{"date":219,"type":39},"2026-03-11",{"date":221,"type":39},"2025-11-03",{"date":223,"type":21},"2029-11",{"name":225,"class":46},"Northwell Health",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":117,"sex":17,"minAge":18,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":47},"100627858","phase-4-application-of-radiomics-for-diagnosis-and-follow-up-of-cardiovascular-device-infections-predict-study-100627858","NCT07454096","Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study","Application of Radiomics in Molecular Imaging (18F-FDG-PET\u002FCT) for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study","PREDICT","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Implanted cardiovascular device (prosthetic valve, TAVI, CIED, vascular graft\u002Fendograft).\n* For infected cohorts: patients studied by FDG-PET with definitive diagnosis of CVDI based on multidisciplinary evaluation.\n* For control group: no clinical suspicion of infection at time of inclusion.\n* Written Informed consent provided (prospective cohort and control group).\n* Women of child-bearing potential must have a negative pregnancy test in serum or urine before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence (only if refraining from heterosexual intercourse during the period of twelve months of duration of the study).\n\nExclusion Criteria:\n\n* Inability to undergo FDG-PET due to contraindications (e.g., allergies, claustrophobia).\n* Pregnancy or breastfeeding.\n* Incomplete clinical data or lack of access to imaging studies.\n* Refusal or withdrawal of informed consent (for control and prospective cohort).","84 Years",{"count":82,"type":21},[237],"PHASE4","Single center, open-label, phase IV clinical trial to study the application of radiomics in molecular imaging for diagnosis and follow-up of CVDIs. The study will include three populations:\n\n* Retrospective cohort (2018-2025)\n* Prospective cohort (2026-2027)\n* Control group (prospective)",[28,240],"Device Related Infection","2026-03-02",{"date":243,"type":39},"2026-03-06",{"date":245,"type":21},"2026-04-30",{"date":247,"type":21},"2028-04-30",{"name":249,"class":46},"Fundacion Clinic per a la Recerca Biomédica",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":272},"100391270","phase-3-heparin-vs-placebo-for-cardiac-catheterization-100391270","NCT04374799","Heparin vs Placebo for Cardiac Catheterization","A Randomized Trial of Heparin vs Placebo in Patients Undergoing Cardiac Catheterization Via the Trans-radial Approach","Inclusion Criteria:\n\n* diagnostic cardiac catheterization; Small size sheath; patency of the ulno-palmar circulation\n\nExclusion Criteria:\n\nabnormal ulno-palmar circulation; Prior radial artery thrombosis; Prior surgery close to the access site; Emergent cardiac catheterization; History of HIT or allergy to heparin; Patients requiring anticoagulation",{"count":258,"type":21},1623,[260],"PHASE3","Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant, low dose anticoagulant and high dose anticoagulant.",[28],"2026-02-18",{"date":265,"type":39},"2026-02-20",{"date":267,"type":39},"2020-10-05",{"date":269,"type":21},"2026-12",{"name":271,"class":46},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",2,{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":283,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":292,"leadSponsor":294,"locationsCount":4},"100619336","ask-questions-about-clinical-trials-100619336","NCT07343297","Ask Questions About Clinical Trials","Ask Questions About Clinical Trials (ASQ - CT): An Implementation Trial of a Communication Intervention to Improve Patient-Provider Communication About Clinical Trials and Provider Invitations to Clinical Trials","ASQ-CT","Inclusion Criteria:\n\n* Age \\> or equal to 18 years\n* Appointment to see a provider at a Karmanos Cancer Institute-McLaren or a medical encounter at McLaren Center for Research and Innovation (MCRI) site for medical\u002Fsystemic treatment\n* Potentially eligible for a clinical trial\n* Speak and read English well enough to be able to understand consent documents and complete surveys\n\nExclusion Criteria:\n\n* Not able to complete study documents on their own physically or cognitively",{"count":282,"type":21},293,[24],"The overall goal of this study is to assess the implementation of the Ask Questions about Clinical Trials (ASQ-CT) brochure, a patient-focused communication tool previously demonstrated to improve patient-provider communication about clinical trials. Participants will be given the ASQ-CT brochure at Time 1 (baseline) and participants will complete a questionnaire at three timepoints, baseline (Time 1), Pre-Research Visit (Time 2), and Post-Research Visit (Time 3).",[286,28,287],"Oncology","Neurologic Disorder","2026-01-06",{"date":290,"type":39},"2026-01-15",{"date":245,"type":21},{"date":293,"type":21},"2027-04-05",{"name":295,"class":46},"Barbara Ann Karmanos Cancer Institute",{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":304,"minAge":18,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":313,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":47},"100529865","one-year-patency-comparison-between-radial-artery-and-no-touch-saphenous-vein-grafts-in-women-undergoing-isolated-cabg-100529865","NCT06179329","One-year Patency Comparison Between Radial Artery and No-touch Saphenous Vein Grafts in Women Undergoing Isolated CABG","No-Touch Saphenous Venous Harvesting TechniQue versUs Radial artEry in Coronary Artery Bypass Grafting in womEN: The QUEEN Multicenter Randomized Controlled Trial","QUEEN","Inclusion Criteria:\n\nWomen aged 18 years or older and younger than 75 years, undergoing isolated and primary myocardial revascularization surgery, with triarterial coronary artery disease (three vessels involved) in vessels subject to surgical revascularization and left ventricular ejection fraction greater than 35%. The target coronary vessels of the study will be those in the territory of the left circumflex artery and the right coronary artery, which must have at least 1.5 mm in diameter, and with proximal obstructive lesions of at least 70%.\n\nExclusion Criteria:\n\n1. Preoperative conditions:\n\n   1. Lack of the patient's written informed consent.\n   2. Presence of poorly controlled diabetes, with a glycated hemoglobin value \\>8 mg\u002Fdl.\n   3. Emergency or salvage surgery, where the intervention needs to be performed quickly due to the critical clinical condition of the patient.\n   4. Renal failure with glomerular filtration rate (creatinine clearance) \\\u003C30 mL\u002Fmin.\n2. Inability to use the saphenous and\u002For radial vein\n\n   1. Positive Allen test using a pulse oximeter\n   2. Presence of abnormal flow detected by means of a Doppler exam in one of the grafts to be used.\n   3. History of vasculitis or Raynaud's syndrome, varicose veins, or history of previous saphenous vein removal\n3. Conditions that may affect patient follow-up\n\n   1. Presence of advanced peripheral arterial disease\n   2. Known contrast allergy: Presence of a documented allergy to the contrast agent used in radiological procedures.\n   3. Impossibility of tracking due to geographic inaccessibility.\n   4. Patients with lack of adherence to guidelines and\u002For prescribed medications.","FEMALE","75 Years",{"count":307,"type":21},150,[24],"The use of a graft from the left internal thoracic artery to the left anterior descending artery has become the gold standard for the indication of coronary artery bypass grafting. However, choosing a graft for the second-best coronary artery, focusing on long-term patency, is still a challenge. The saphenous vein using the \"no-touch\" technique is an alternative to a radial artery graft, but there is little evidence, especially in women. This randomized clinical study aims to compare the patency of these grafts in the second-best coronary artery in women undergoing coronary artery bypass grafting.",[28,311,312],"Surgery-Complications","Graft Failure",[314,315,316,317],"Cardiovascular Surgery","Coronary Disease","Women","Graft patency","2025-12-04",{"date":320,"type":39},"2025-12-12",{"date":322,"type":39},"2024-01-01",{"date":324,"type":21},"2027-12-30",{"name":326,"class":46},"University of Sao Paulo General Hospital",{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":47},"100614041","the-clinical-value-of-deep-learning-based-reconstruction-techniques-in-cardiac-mri-scanning-100614041","NCT07274436","The Clinical Value of Deep Learning-Based Reconstruction Techniques in Cardiac MRI Scanning","Inclusion Criteria:\n\n1. Patients requiring cardiac MRI in clinical practice;\n2. Patient age ≥ 18 years;\n3. The patient has signed an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with contraindications to magnetic resonance imaging;\n2. Patients who failed to complete the MRI examination or whose image quality was inadequate for diagnostic requirements;\n3. Other circumstances deemed by clinical trial personnel as unsuitable for participation in this trial;\n4. Subjects or their legal guardians voluntarily requesting to withdraw.",{"count":334,"type":21},50,"By enrolling patients who underwent cardiac MR(Magnetic Resonance) examinations at our center and using randomized allocation, the patients were divided into a study group and a control group. The study group underwent scanning using AI-based(Artificial Intelligence-based) cardiac MRI(Magnetic Resonance Imaging) sequences, while the control group was scanned using non-AI cardiac MRI sequences",[28],"2025-11-27",{"date":339,"type":39},"2025-12-10",{"date":341,"type":39},"2025-08-01",{"date":343,"type":21},"2026-08-01",{"name":345,"class":46},"Lian Yang",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":17,"minAge":353,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":47},"100525153","phase-3-effect-of-colchicine-on-perioperative-anti-inflammatory-organ-injury-in-cardiac-surgery-100525153","NCT06118034","Effect of Colchicine on Perioperative Anti-inflammatory Organ Injury in Cardiac Surgery","Effect of Colchicine on Perioperative Anti-inflammatory Organ Injury in Cardiac Surgery : a Multi-center, Randomized, Controlled, Double-blind Clinical Trial","Inclusion criteria\n\n1. Aged between 50 and 80 years, male or female;\n2. Patients undergoing elective cardiac surgery;\n3. Have signed the informed consent form (ICF).\n\nExclusion criteria\n\n1. Patients undergoing emergency surgery;\n2. Patients undergoing deep hypothermic circulatory arrest surgery;\n3. Preoperative predicted mortality \\>3% according to European System for Cardiac Operative Risk Evaluation II (EuroSCORE II);\n4. Patients undergoing off-pump coronary artery bypass grafting (off-pump CABG) surgery;\n5. Patients undergoing left or right ventricular outflow tract obstruction surgery;\n6. Patients undergoing complex corrective surgery for congenital heart disease;\n7. Patients with an expected CPB exceeding 180 minutes or an anticipated aortic cross-clamp time exceeding 120 minutes;\n8. Patients expected to have a postoperative endotracheal tube removal time exceeding 24 hours;\n9. Patients with prolonged fasting or inability to self-feed;\n10. A history of malignant tumor;\n11. Patients with unstable preoperative vital signs requiring intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation (ECMO)assistance, or endotracheal tube-assisted ventilation;\n12. A history of cardiac surgery;\n13. Patients with preoperative gastrointestinal symptoms, such as nausea, vomiting and diarrhea;\n14. Patients with a history of dialysis before surgery;\n15. Patients with a history of atrial fibrillation before surgery;\n16. Patients on long-term hepatorenal protective medications;\n17. Patients with hepatic and renal insufficiency (Child-Pugh class B or C, estimated glomerular filtration rate \\\u003C35 mL\u002Fmin\u002F1.73 m2);\n18. Patients with abnormal baseline inflammatory markers \\[interleukin-6 (IL6) \\>10 pg\u002FmL, procalcitonin (PCT) \\>0.5 ng\u002FmL, C reactive protein (CRP) \\>10 mg\u002FL\\];\n19. Patients diagnosed with infectious diseases, inflammatory immune diseases, or tumor;\n20. Patients who have received immunosuppressive or anti-inflammatory treatment;\n21. Patients allergic or intolerant to colchicine;\n22. Breastfeeding or pregnant women;\n23. Other situations deemed inappropriate for participation in the study by the investigator.","50 Years","80 Years",{"count":356,"type":21},768,[260],"All patients will be completed collection of demographic data, clinical data, and be observed for inflammatory organ damage, oxygenation index or SpO2\u002F FIO2, WBC, NEU, interleukin-1β, interleukin-6, interleukin-8 (IL-1β\u002F6\u002F8), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), procalcitonin (PCT), myoglobin (Myo), creatine kinase-MB (CK-MB), high-sensitivity cardiac troponin T (hs-cTnT), neutrophil elastase (NE), myeloperoxidase (MPO), APACHE II score, alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, Murray lung injury score, serum creatinine, eGFR, mechanical ventilation time, ICU length of stay, drug-related gastrointestinal reactions, and 30-day and 90-day all-cause mortality, among other indicators.",[360,28],"Inflammatory Response","2025-11-13",{"date":363,"type":39},"2025-11-17",{"date":365,"type":39},"2024-01-28",{"date":367,"type":21},"2026-12-30",{"name":369,"class":46},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":378,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":47},"100443547","opportunistic-pkpd-trial-in-critically-ill-children-optic-100443547","NCT05055830","Opportunistic PK\u002FPD Trial in Critically Ill Children (OPTIC)","Clinically Integrated Opportunistic PK\u002FPD Trial in Critically Ill Children","OPTIC","Inclusion Criteria:\n\nTo be eligible for enrollment, a potential participant must meet all the following criteria:\n\n1. Participant is \\\u003C21 years old on admission\n2. Participant is admitted to the Pediatric Cardiac Intensive Care Unit\n3. Parent\u002Flegal guardian\u002Fadult participant can understand the consent process and is willing to provide informed consent\u002Fassent\n4. Participant is receiving one or more of the study drugs of interest at the time of enrollment\n\nExclusion Criteria:\n\n1\\. Any condition which would make the participant, in the opinion of the investigator, unsuitable for the study","0 Months","20 Years",{"count":381,"type":21},2000,"OPTIC is a prospective, open-label, non-randomized study of multiple medications administered to approximately 2000 children in the pediatric cardiac intensive care unit (PCICU) per routine clinical car by their treating provider. The purpose of this study is to characterize the PK of drugs routinely administered to children per standard of care using opportunistic and scavenged samples. The prescribing of drugs to children will not be part of this protocol.\n\nAfter the child\u002Fadult (\\\u003C21 years of age) is consented\u002Fenrolled, demographic and clinical data will be extracted from the EHR. Biospecimen information (including date and time of sample collection) will be collected.\n\nData analysis will be conducted on all participants with at least 2 evaluable samples. The protocol represents minimal risk to the children\u002Fadults who provide body fluid for this study, including potential loss of confidentiality (samples will be assigned a unique accession number) and risks associated with blood draws. Adverse Events (AEs)\u002FSerious Adverse Events (SAEs) caused by the study specimen collections will be monitored and recorded in the Electronic Data Capture (EDC) system.",[28,384,385],"Critically Ill","Children, Adult",{"date":387,"type":39},"2025-11-14",{"date":389,"type":39},"2021-10-05",{"date":391,"type":21},"2028-10-30",{"name":393,"class":46},"Duke University",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":354,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":403,"conditions":404,"keywords":407,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":4},"100605338","implementation-of-new-exercise-protocols-in-cardiac-rehabilitation-100605338","NCT07161219","Implementation of New Exercise Protocols in Cardiac Rehabilitation.","REVACARD","Inclusion Criteria:\n\n\\- Patient meeting the conditions of the permanent life support agreement following hospitalization for a cardiac condition such as: acute myocardial infarction; coronary surgery; therapeutic percutaneous endovascular intervention on the coronary arteries, under medical imaging guidance; therapeutic percutaneous endovascular intervention on the heart, under medical imaging guidance; surgery for congenital or acquired heart malformation; surgery for valvular lesion; heart transplantation; resistant angina (to be specified by detailed history, medical history, and technical examinations, justifying multidisciplinary care); cardiomyopathy with left ventricular dysfunction (to be specified by detailed history, medical history, and technical examinations, justifying multidisciplinary care).\n\n* Patient aged between 18 and 80 years.\n* Patient capable of giving informed consent.\n* Patient registered for permanent life support at the CuSL.\n* Patient capable of understanding instructions in French. - Patient with prior medical consent and clinically stable.\n\nExclusion Criteria:\n\n* \\- Minor (\\\u003C18 years old).\n* Pregnant woman.\n* Patient unable to provide informed consent.\n* Patient with cognitive, neurological, or orthopedic limitations.\n* Patient with mobility or musculoskeletal difficulties incompatible with physical activity.\n* Clinical instability.",{"count":20,"type":21},[24],"* Primary Objective: To evaluate the effects of complementary exercise protocols in cardiac rehabilitation (CR), such as inspiratory muscle training (IMT), by assessing inspiratory muscle strength.\n* Secondary Objectives: To assess functional capacity, quality of life (QoL), and pulmonary function.",[405,28,406],"Heart Diseases","Inspiratory Muscle Training",[95,408],"inspiratory muscles training","2025-09-18",{"date":411,"type":39},"2025-09-23",{"date":413,"type":21},"2025-12-01",{"date":415,"type":21},"2029-12-31",{"name":417,"class":46},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":424,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":428,"conditions":429,"keywords":431,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":47},"100503268","rectus-sheath-block-in-cardiac-surgery-100503268","NCT05833048","Rectus Sheath Block in Cardiac Surgery","Inclusion Criteria:\n\n* In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n  1. Adults 18-85 years old\n  2. Scheduled to undergo cardiac procedures involving chest tubes\n  3. Male or female\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. ASA class V\n  2. Urgent or emergent surgery\n  3. Contraindications to administration of local anesthesia (e.g. local anesthetic allergy)\n  4. History of substance abuse or chronic opioid use\n  5. Patient refusal or inability to consent","85 Years",{"count":426,"type":21},75,[24],"This is a prospective, randomized study. The purpose of this study is to evaluate the effect of post-surgical pain control of a type of peripheral nerve block, Rectus Sheath Block.\n\n1. Does the rectus sheath block decrease opioid consumption postoperatively after cardiac surgery?\n2. Does the rectus sheath block decrease VAS pain scores postoperatively after cardiac surgery? Study participants will be assigned to receive either rectus sheath block or no block.",[28,430],"Postoperative Pain",[432,433],"cardiac surgery","regional anesthesia",{"date":411,"type":39},{"date":436,"type":39},"2024-07-29",{"date":438,"type":21},"2026-09-07",{"name":440,"class":46},"Icahn School of Medicine at Mount Sinai",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":22,"phases":451,"briefSummary":452,"conditions":453,"keywords":461,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":47},"100475904","phase-3-evaluation-of-low-dose-colchicine-and-ticagrelor-in-prevention-of-ischemic-stroke-in-patients-with-stroke-due-to-atherosclerosis-100475904","NCT05476991","Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis","Reducing Inflammation in Ischemic Stroke With Colchicine, and Ticagrelor in High-risk Patients-extended Treatment in Ischemic Stroke","RIISC-THETIS","Inclusion criteria:\n\nPatient should have the following:\n\nPatient with:\n\n1. Cerebral infarction (CI) proven by neuro-imaging (MRI or head-CT), immediately once the neurologic deficit is stabilized (investigator judgement) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event (TIA with documented ischemic lesion (MRI or CT) in the appropriate area corresponding to the symptoms will be considered CI, following the current definition)\n2. Or TIA lasting more 10 minutes or more (with motor symptoms or aphasia\u002Fdysarthria or visual defect), with total resolution and no brain lesion on neuro-imaging (TIA) and with ipsilateral carotid stenosis that was revascularized (endarterectomy or stenting) or with ipsilateral, potentially causal intracranial stenosis ≥70%) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event\n3. and documented atherosclerotic stenosis:\n\n   1. presence of carotid atherosclerotic stenosis (on the basis of carotid duplex, CTA, MRA, XRA - only the report will be required to document atherosclerotic disease) ipsilateral to the cerebral ischemic symptoms (stenosis defined by luminal narrowing ≥30%, judgement of the investigator)\n   2. or presence of atherosclerotic stenosis of another cerebral artery (documented vertebral artery stenosis, basilar artery stenosis, other intracranial artery stenosis) ipsilateral to the ischemic area (stenosis defined by luminal narrowing ≥30%, judgement of the investigator)\n   3. or presence of atherosclerotic disease of the aortic arch with a plaque ≥4mm in thickness with or without superimposed thrombus, or a plaque \\\u003C4 mm with a superimposed mobile thrombus (detected by transesophageal echocardiography or CT angiography)\n4. with no clear indication of colchicine treatment (gout, Mediterranean fever) and with an indication to long-term antiplatelet therapy (no clear indication to oral anticoagulant)\n5. age equal or above 18\n6. Rankin score less than ≤4 (ranges from 0 to 6, with 0 indicating no symptoms, 1 no disability, 2 to 3 needing some help with daily activities, 4 to 5 dependent or bedridden, and 6 death),\n7. fully informed and signed inform consent\n8. with social security number.\n9. medical examination before the participation to the research\n10. Under contraception in case of childbearing potential (highly effective: 1) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation et 2) progestogen-only).\n11. Pregnancy test for women of childbearing potential\n\nExclusion Criteria:\n\n1. Colchicine treatment needed (e.g., gout, Mediterranean fever)\n2. Hypersensitivity to ticagrelor or any of the excipients.\n3. Hypersensitivity to colchicine or any of the excipients.\n4. Major digestive disorders (chronic diarrhea, inflammatory disease of the digestive tract as uncontrolled ulcerative colitis or active Crohn disease)\n5. Immunosuppression, medullary aplasia\n6. Active chronic inflammatory disease, chronic active infection, evolving cancer\n7. Hemodynamic instability (need for amines for more than 24 hours, circulatory assistance)\n8. A recent severe sepsis (7 days) or all recent acute reaches\n9. Chronic treatment (for more than 6 months) with corticosteroids or NSAIDs (or repeated high-dose intake for less than 7 days).\n10. Anticipated concomitant oral or intravenous therapy with strong CYP3A4 inhibitors or CYP3A4 substrates than cannot be stopped for the course of the course of this study\n11. CI\u002FTIA due to arterial dissection (as documented following the judgment of the investigator) or due to cardiac source of embolism without documented atherosclerotic disease (e.g., mitral stenosis or endomyocardial fibrosis, endocarditis) a patient with atrial fibrillation, or with a history of myocardial infarction, or with calcified aortic stenosis will be eligible if the above inclusion criteria are also met\\]\n12. Indication to long-term oral anticoagulant treatment (e.g., atrial fibrillation)\n13. Symptomatic hemorrhagic stroke (the mere presence of asymptomatic cerebral hemosiderin deposits -so called \"microbleedings\" - on gradient echo imaging is not an exclusion criteria)\n14. Active pathological bleeding\n15. Uncontrolled hypertension (investigator judgement)\n16. Follow-up visit impossible or anticipated bad compliance.\n17. Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits..\n18. Anticipated pregnancy at time of enrollment in the study\n19. Breastfeeding woman\n20. Patients participating in another pharmaco therapeutic program with an experimental therapy that is known to affect the ticagrerlor, colchicine or aspirine therapy.\n21. Leukopenia \\\u003C3000\u002Fμl\n22. Patients with severe renal impairment (creatinine clearance \\\u003C 30 ml\u002Fmin)\n23. Patients with severe hepatic impairment\n24. Prohibited treatments: All treatments contraindicated during the use of colchicine and\u002For ticagrelor",{"count":450,"type":21},2800,[260],"REDUCING INFLAMMATION IN ISCHEMIC STROKE WITH COLCHICINE, AND TICAGRELOR IN HIGH-RISK PATIENTS-EXTENDED TREATMENT IN ISCHEMIC STROKE.",[454,455,456,457,458,459,28,460],"Stroke","Stroke, Ischemic","Atherosclerosis","Myocardial Infarction","Coronary Syndrome","TIA","Cerebral Infarction",[454,462,456,463,464],"Colchicine","Aspirin","Ticagrelor","2025-09-01",{"date":467,"type":39},"2025-09-08",{"date":469,"type":39},"2023-05-17",{"date":471,"type":21},"2027-09-01",{"name":473,"class":46},"Assistance Publique - Hôpitaux de Paris",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":480,"targetDuration":482,"studyType":59,"phases":4,"briefSummary":483,"conditions":484,"keywords":488,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":4},"100385175","quality-of-cardiopulmonary-resuscitation-pre--and-intra-hospital-100385175","NCT04295291","Quality of Cardiopulmonary Resuscitation Pre- and Intra Hospital","Inclusion Criteria:\n\n* cardiac arrest (all reasons)\n* a defibrillator has been used\n* over 18 years\n* cardiopulmonary resuscitation has been conducted\n\nExclusion Criteria: N\u002FA",{"count":481,"type":21},300,"6 Months","The survival after intrahospital cardiac arrest has been reported to 15%. In Norway this varies between 16 and 23%.). Many factors are associated with survival after cardiac arrest, both intra- and prehospital. Recent studies have not included information about individual patient factors and the outcome after cardiopulmonary resuscitation (CPR). In the current hospital, we are able to record patient specific information related to a cardiac arrest\u002FCPR situation, and thereby be able to assess patient-related factors associated with both detection, treatment and outcome of CPR.",[485,486,487,28],"Cardiac Death","Cardiac Arrest","Cardiac Arrhythmia",[489,490,491,492,493,494],"Cardiopulmonary resuscitation","Defibrillation","Ventilation","Quality","Mortality","Morbidity","2025-08-03",{"date":497,"type":39},"2025-08-05",{"date":499,"type":21},"2026-01-01",{"date":501,"type":21},"2028-12-31",{"name":503,"class":46},"Ostfold University College",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":117,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":47},"100503033","development-of-an-artificial-intelligence-algorithm-to-detect-pathological-repolarization-disorders-on-the-ecg-and-the-risk-of-ventricular-arrhythmias-100503033","NCT05829993","Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias","DEEPECG4U","Inclusion Criteria:\n\n* Age ≥ 18\n* Patients or subjects taken care in recruiting centres for which an ECG is indicated\n* No opposition to participation in the study\n\nExclusion Criteria:\n\n* Medical contraindication for ECG\n* Subjects with pacemaker-driven QRS",{"count":512,"type":21},5000,"Torsades de Pointes (TdP) are potentially fatal ventricular arrhythmias that are promoted by prolonged ventricular repolarization (Long QT, LQT). The different forms of LQT result from inhibition of cardiac potassium currents (IKr and IKs) or activation of a late sodium current (INaL). These alterations may be either congenital (3 types: cLQT-1: IKs, cLQT-2: IKr, cLQT-3: INaL) or drug-induced (diLQT, via inhibition of IKr).\n\nMore than 100 medications have received marketing authorization despite a known risk of TdP, due to a favorable benefit-risk ratio (e.g., hydroxychloroquine).\n\nQTc, which represents the duration of ventricular repolarization (in milliseconds) - defined as the time from the beginning of the QRS complex to the end of the T wave, corrected for heart rate - is prolonged in all forms of LQT.\n\nSpecific T-wave abnormalities, depending on the altered ion currents, have been described and can help differentiate the various types of congenital or drug-induced LQT.\n\nHowever, screening for LQT and TdP risk, both at the individual and population levels, currently relies mainly on isolated QTc evaluation and genetic testing, which often takes considerable time to return.\n\nThus, limiting ECG analysis to QTc measurement alone offers low predictive value, as the ECG contains a wealth of additional information beyond a single interval.\n\nThe investigator recently demonstrated that artificial intelligence (AI)-based ECG analysis using deep-learning convolutional neural networks can detect more discriminative features of the ECG for predicting the type of LQT and the risk of TdP, going beyond QTc alone.\n\nUsing these techniques, the investigator developed a model with probabilistic modules capable of: predicting TdP risk, identifying LQT subtypes (scores ranging from 0 to 100%), and quantitatively measuring ECG parameters such as QTc, heart rate, PR, and QRS duration.\n\nThe objective of this project is to prospectively validate our model in real-world conditions across various departments within AP-HP, for:\n\nAutomatic measurement of QTc, and Identification and classification of LQT types and TdP risk.",[28,515],"Ventricular Arrythmia",[517,518,519,520,521],"Artificial intelligence","ECG","Repolarization","QT","Ventricular arrhythmias","2025-07-28",{"date":524,"type":39},"2025-07-31",{"date":526,"type":39},"2023-11-28",{"date":528,"type":21},"2027-06-28",{"name":473,"class":46},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":537,"enrollmentInfo":538,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":539,"conditions":540,"keywords":541,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":548,"leadSponsor":549,"locationsCount":109},"100595866","external-validation-of-artificial-intelligence-enabled-electrocardiography-ai-ecg-for-the-detection-of-left-ventricular-dysfunction-lvd-100595866","NCT07038018","External Validation of Artificial Intelligence-enabled Electrocardiography (AI-ECG) for the Detection of Left Ventricular Dysfunction (LVD)","External Validation of Artificial Intelligence-Enabled Electrocardiograms for the Detection of Reduced Left Ventricular Ejection Fraction","Inclusion Criteria:\n\n* patients with ECGs and an echocardiogram within 7 days\n\nExclusion Criteria:\n\n* Missing ECG signals\n* Missing LVEF assessment in echocardiograms","100 Years",{"count":57,"type":21},"This is a multi-center, retrospective study evaluating the performance of an artificial intelligence-enabled electrocardiography (AI-ECG) algorithm in detecting reduced left ventricular ejection fraction (LVEF ≤ 40%). All included patients from participating hospitals must have undergone a digital 12-lead electrocardiogram (ECG) and an echocardiogram with assessment of LVEF within seven days. The AI-ECG algorithm will be applied to evaluate its diagnostic performance, which will be further assessed across subgroups stratified by demographic characteristics and clinical factors.",[28],[542,543],"left ventricular dysfunction","artificial intelligence","2025-06-25",{"date":546,"type":39},"2025-06-26",{"date":341,"type":21},{"date":177,"type":21},{"name":550,"class":46},"Tri-Service General Hospital",{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":4,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":558,"targetDuration":4,"studyType":22,"phases":559,"briefSummary":560,"conditions":561,"keywords":564,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":47},"100531905","high-versus-low-dose-serratus-anterior-plane-block-after-minimally-invasive-valve-surgery-100531905","NCT06205875","High Versus Low Dose Serratus Anterior Plane Block After Minimally Invasive Valve Surgery.","High Versus Low Dose Serratus Anterior Plane Block After Minimally Invasive Valve Surgery: a Double-blinded Randomized Controlled Trial.","Inclusion Criteria:\n\n* Scheduled for elective aortic valve surgery or elective mitral valve surgery via right anterolateral thoracotomy\n* Adult patients (minimally 18 years old)\n* Bodyweight \\> 50kg\n* EuroScore ii \\\u003C 3%\n\nExclusion Criteria:\n\n* Refusal to participate\n* Inability to communicate due to language or neurologic barriers\n* Inability to control and self-administer opioids with PCIA or to comprehend the NRS pain score due to confusion or learning difficulties\n* Chronic use of opioids\n* Chronic use of analgesic antidepressants and\u002For antiepileptics\n* Use of prohibited medication which possibly interacts with bupivacaine-epinephrine or opioids (mexiletine, ketoconazole, theophylline, IMAO, Digitalis and cimetidine)\n* History of major trauma or surgery to right chest wall\n* History of chronic pain at right chest wall\n* Allergy to opioids and\u002For local anesthetics\n* Allergy to paracetamol\n* Class 3 obesity (BMI 40 or more)\n* Pregnancy\n* Intraoperative events compromising early postoperative recovery (aortic dissection, systolic anterior motion of the mitral valve, cardiac tamponade, brady-arrhytmias requiring external pacing,...)",{"count":191,"type":21},[24],"This study aims to compare the efficacy and quality of pain relief provided by the high-dose serratus anterior plane (SAP) block with the standard SAP block in preventing and treating acute postoperative pain after total endoscopic aortic or mitral valve surgery.",[562,215,28,563],"Analgesia","Post Operative Pain",[565,566,567,568],"Aorta\u002Fmitral valve surgery","Serratus anterior plane block","Enhanced recovery after surgery","post operative pain","2025-05-12",{"date":571,"type":39},"2025-05-14",{"date":573,"type":39},"2024-02-21",{"date":575,"type":21},"2027-12-31",{"name":577,"class":46},"Jessa Hospital",{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":117,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":22,"phases":587,"briefSummary":588,"conditions":589,"keywords":590,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":47},"100506697","validation-of-multi-contrast-high-resolution-cardiac-magnetic-resonance-imaging-100506697","NCT05877755","Validation of Multi-contrast, High-resolution Cardiac Magnetic Resonance Imaging","Validation of Multi-contrast, High-resolution Cardiac Magnetic Resonance Imaging (CARDIO IRM)","CARDIO-IRM","Inclusion Criteria:\n\n* Adult patient (over 18 years of age) requiring an MRI scan as part of their care.\n* Male or female.\n* Affiliated or beneficiary of a social security scheme\n* Having given his\u002Fher oral no objection after having read the information note\n\nExclusion Criteria:\n\n* Patient unable to give oral consent (guardianship, non-French speaker, etc.)\n* Patient deprived of liberty\n* Patient who does not meet the specific eligibility criteria for an MRI examination: pregnant women, known pathology that may interfere with acquisition (e.g. Parkinson's disease), absolute or relative contraindication to an MRI examination\n* Patient participating in a therapeutic interventional trial or in a period of relative exclusion in relation to another protocol",{"count":82,"type":21},[24],"Cardiovascular disease (CVD) causes at least 1.8 million European deaths annually, exceeding fatalities from cancer, chronic respiratory disease, and diabetes. Consequently, the fight against CVD has become the main priority of the World Health Organization. In the pursuit of understanding and treating CVD, cardiac magnetic resonance imaging (CMR) has remained the only modality capable of providing a comprehensive assessment of the heart's function and structure without harmful radiation. Unfortunately, current CMR systems remain too slow, too complex, require highly trained specialists and, as such, have presented a barrier to a wider adoption of CMR. The aim of CARDIO-IRM is to unleash the full potential of CMR to transform patient trajectories by introducing a fast, one-click, fully automated, and comprehensive imaging pipeline applicable to diagnosis, prognosis, and therapy selection in cardiology.",[28],[591,592,593,594,595],"Cardiac MRI","Sequences","High-resolution","Multi-contrast","Imaging","2025-04-16",{"date":598,"type":39},"2025-04-22",{"date":600,"type":39},"2025-04-15",{"date":602,"type":21},"2030-03-31",{"name":604,"class":46},"University Hospital, Bordeaux",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":614,"conditions":615,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":47},"100468312","continuous-wireless-monitoring-of-vital-signs-and-automated-alerts-in-participants-at-home-and-during-hospitalization-100468312","NCT05378139","Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Participants at Home and During Hospitalization","WARD Prospective Study - Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Participants at Home and During Hospitalization","Inclusion Criteria:\n\n* Adult participants (≥18 years)\n* Patients assessed by the clinical staff as having an acute condition with risk for clinical deterioration and being either at home (with no apparent need for hospitalization), and\u002For in hospital OR\n* Patients at either at home before, in-hospital and\u002For after hospitalization for elective major surgery, defined as surgery lasting more than one hour under general- or regional anaesthesia\n\nExclusion Criteria:\n\n* The participant expected not to cooperate with study procedures.\n* Allergy to plaster or silicone.\n* Having pacemaker or Implantable Cardioverter Defibrillator (ICD) device.\n* Inability to give informed consent.",{"count":613,"type":21},3095,"The primary aim of this study is to test and assess the implementation and effectiveness of continuous wireless vital signs monitoring with real-time alerts on:\n\nThe frequency of patients monitored with adequate data quality as adequate clinical user satisfaction in the initial versus the last part of the trial (primary outcome).",[616,617,618,286,28,619],"Surgical Complication","Pulmonary Disease","Hematologic Diseases","Infections","2025-04-08",{"date":622,"type":39},"2025-04-11",{"date":624,"type":39},"2021-02-01",{"date":626,"type":21},"2025-12-22",{"name":628,"class":46},"University Hospital Bispebjerg and Frederiksberg",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":635,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":636,"conditions":637,"keywords":642,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":47},"100585126","utility-of-gene-test-analysis-for-diagnosis-prognosis-and-treatment-of-patients-with-genetic-arrhythmic-heart-disease-the-arrhythmic-gene-heart-100585126","NCT06898307","Utility of Gene Test Analysis for Diagnosis, Prognosis and Treatment of Patients With Genetic Arrhythmic Heart Disease: the ARRHYTHMIC GENE-HEART","Inclusion Criteria:\n\n* Patients evaluated at the Cardiogenetic Center of the University of Ferrara in Ferrara, Italy.\n* Having a proven cardiogenetic disease\n\nExclusion Criteria:\n\n* Refuse to provide informed consents\n* Patients not having a cardiogenic disease",{"count":82,"type":21},"The goal of this observational study is to enroll all patients evaluated at the specialized Cardiogenetic Center within the Cardiology Department of the University of Ferrara, Italy. The primary aim of the registry is to collect comprehensive clinical, genetic, and electrophysiological data from individuals with suspected or confirmed arrhythmogenic conditions. By systematically documenting patient demographics, family history, clinical presentations, diagnostic findings, and treatment outcomes, the registry seeks to enhance our understanding of the genetic basis and clinical implications of genetically driven arrhythmias and systemic syndromes. This registry will facilitate long-term follow-up of enrolled patients to assess the natural history of arrhythmogenic disorders and the effectiveness of various therapeutic interventions. Additionally, it aims to identify potential risk factors associated with adverse outcomes, such as sudden cardiac death or major arrhythmic events.",[638,28,639,640,641],"Genetic Disease","Cardiac Arrhythmias","Genetic Disorder","Cardiology",[643],"Cardiogenetic","2025-03-26",{"date":646,"type":39},"2025-03-27",{"date":648,"type":39},"2017-11-01",{"date":650,"type":21},"2035-11-01",{"name":652,"class":46},"University Hospital of Ferrara"]